肿瘤坏死因子样凋亡微弱诱导剂与动脉粥样硬化
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:

国家科技支撑计划(2008BAI68B02)


Tumor Necrosis Factor-Like Weak Inducer of Apoptosis and Atherosclerosis
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的肿瘤坏死因子样凋亡微弱诱导剂是肿瘤坏死因子超家族成员。通过与受体Fn14结合,肿瘤坏死因子样凋亡微弱诱导剂从多方面参与动脉粥样硬化的发生发展过程,如促进炎症反应、促进基质金属蛋白酶9产生、上调血管内皮生长因子表达等。肿瘤坏死因子样凋亡微弱诱导剂参与动脉粥样硬化疾病如冠心病及其危症糖尿病的发病过程,他汀类药物通过减少循环中肿瘤坏死因子样凋亡微弱诱导剂-Fn14量而可能有益于动脉粥样硬化的治疗。

    Abstract:

    Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of tumor necrosis factor (TNF) super family. Combining with its receptor Fn14,TWEAK can participate in the process of atherosclerosis (As) through several ways,including inducing inflammation,augmenting the expression of MMP9,promoting neovascularization and so on. TWEAK is involved in coronary heart disease and its equivalent-diabetes mellitus. Statins may play a potential role in the treatment of As by reducing TWEAK-Fn14 complex in blood.

    参考文献
    相似文献
    引证文献
引用本文

谢遥,程晓曙.肿瘤坏死因子样凋亡微弱诱导剂与动脉粥样硬化[J].中国动脉硬化杂志,2010,18(6):492~494.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2010-02-01
  • 最后修改日期:2010-06-15
  • 录用日期:
  • 在线发布日期: